Edition:
United Kingdom

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

3.55USD
14 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.55
Open
$3.60
Day's High
$3.85
Day's Low
$3.55
Volume
11,556
Avg. Vol
11,749
52-wk High
$6.45
52-wk Low
$2.12

Latest Key Developments (Source: Significant Developments)

aTyr Pharma reports qtrly ‍net loss per share, basic and diluted $0.43​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - aTyr Pharma Inc ::aTyr Pharma announces third quarter 2017 operating results and provides corporate update.aTyr Pharma Inc - ‍expects that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into middle of 2019​.aTyr Pharma Inc qtrly ‍net loss per share, basic and diluted $0.43​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Atyr Pharma says ‍John Mendlein transitions from CEO to non-executive board member​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Atyr Pharma Inc ::Atyr Pharma announces leadership transition.Atyr Pharma Inc - ‍John Mendlein transitions from CEO to non-executive board member​.Atyr Pharma Inc - ‍Sanjay Shukla appointed president and CEO​.  Full Article

Atyr Pharma announces promising top-line results from Resolaris
Monday, 24 Apr 2017 

April 24 (Reuters) - Atyr Pharma Inc :Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy.Resolaris generally well-tolerated at doses up to 3.0 mg/kg once weekly in early onset facioscapulohumeral muscular dystrophy.Atyr believes observed safety results of Resolaris to date are supportive of further advancement of resolaris.  Full Article

aTyr Pharma reports signals of clinical activity in genetically distinct Myopathies with Resolaris in exploratory trials
Tuesday, 13 Dec 2016 

aTyr Pharma Inc - : Top-Line results from a completed phase 1b/2 trial for adult patients with limb-girdle muscular dystrophy 2b . Says resolaris continues to demonstrate a generally well tolerated safety profile in all trials .Reports promising signals of clinical activity in multiple rare genetically distinct myopathies with resolaris™ in exploratory trials.  Full Article

Atyr Pharma Inc qtrly loss per share $0.65
Wednesday, 10 Aug 2016 

Atyr Pharma Inc : Atyr Pharma announces second quarter 2016 operating results . Atyr Pharma Inc qtrly loss per share $0.65 .Currently expect that our cash, cash equivalents and investments will be sufficient to fund our anticipated operations into 2018..  Full Article

Atyr Pharma qtrly loss per share $0.68
Wednesday, 11 May 2016 

Atyr Pharma Inc : Qtrly loss per share $0.68 .Atyr pharma announces first quarter 2016 operating results.  Full Article

BRIEF-aTyr Pharma reports qtrly ‍net loss per share, basic and diluted $0.43​

* aTyr Pharma announces third quarter 2017 operating results and provides corporate update